Most Read

Magrolimab is an investigational monoclonal antibody, which has been developed to act against CD47 and macrophage checkpoint inhibitor. It is being developed in various hematologic and solid tumour

Situated at the company’s R&D headquarters in Boston, the new facility offers end-to-end research and development services to advance the development of next-generation cell therapies. The new R&D

HFB30132A is said to have been discovered, engineered, and developed in less than six months by the US-based HiFiBiO Therapeutics. The company said that its partnership with ABL

As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets

Dupixent, a fully-human monoclonal antibody, blocks the signalling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. The regulator has provided breakthrough therapy device designation based on data from

The company has reported positive pre-clinical results and confirmed the efficacy of the vaccine on the live SARS CoV-2 virus. ACvac1 is a prophylactic COVID-19 vaccine designed to

The fine has been imposed on the companies for pushing the sales of Lucentis to treat age-related macular degeneration (AMD) over Avastin, which is available at low cost

AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved

Under the deal, Mylan will acquire Aspen’s portfolio that includes injectable anticoagulants marketed in Europe under the brand names and variations of the brand names such as Arixtra,